These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 27558398)

  • 21. One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study.
    Lim CH; Lin CH; Chen DY; Chen YM; Chao WC; Liao TL; Chen HH
    PLoS One; 2016; 11(11):e0166339. PubMed ID: 27832150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prealbumin, platelet factor 4 and S100A12 combination at baseline predicts good response to TNF alpha inhibitors in rheumatoid arthritis.
    Nguyen MVC; Baillet A; Romand X; Trocmé C; Courtier A; Marotte H; Thomas T; Soubrier M; Miossec P; Tébib J; Grange L; Toussaint B; Lequerré T; Vittecoq O; Gaudin P
    Joint Bone Spine; 2019 Mar; 86(2):195-201. PubMed ID: 29885551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors.
    Hernández-Breijo B; Navarro-Compán V; Plasencia-Rodríguez C; Parodis I; Gehin JE; Martínez-Feito A; Novella-Navarro M; Mezcua A; Warren DJ; Nozal P; Pascual-Salcedo D; Balsa A
    Sci Rep; 2021 Jun; 11(1):11632. PubMed ID: 34079038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-132, miR-146a, and miR-155 as potential biomarkers of methotrexate response in patients with rheumatoid arthritis.
    Singh A; Patro PS; Aggarwal A
    Clin Rheumatol; 2019 Mar; 38(3):877-884. PubMed ID: 30511295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis.
    Tao W; Concepcion AN; Vianen M; Marijnissen ACA; Lafeber FPGJ; Radstake TRDJ; Pandit A
    Arthritis Rheumatol; 2021 Feb; 73(2):212-222. PubMed ID: 32909363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study.
    Raaschou P; Frisell T; Askling J;
    Ann Rheum Dis; 2015 Dec; 74(12):2137-43. PubMed ID: 25107559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
    Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
    Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
    Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
    J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement.
    Bouman C; van Herwaarden N; van den Hoogen F; van der Maas A; van den Bemt B; den Broeder AA
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):597-604. PubMed ID: 28425772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimizing biological treatment in rheumatoid arthritis with the aid of therapeutic drug monitoring.
    Eng GP
    Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M; Kaneko Y; Kondo H; Takeuchi T
    Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis.
    Lopez-Rodriguez R; Perez-Pampin E; Marquez A; Blanco FJ; Joven B; Carreira P; Ferrer MA; Caliz R; Valor L; Narvaez J; Cañete JD; Ordoñez MDC; Manrique-Arija S; Vasilopoulos Y; Balsa A; Pascual-Salcedo D; Moreno-Ramos MJ; Alegre-Sancho JJ; Navarro-Sarabia F; Moreira V; Garcia-Portales R; Raya E; Magro-Checa C; Martin J; Gomez-Reino JJ; Gonzalez A
    PLoS One; 2018; 13(5):e0196793. PubMed ID: 29734345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating miR-10a as Predictor of Therapy Response in Rheumatoid Arthritis Patients Treated with Methotrexate.
    Hong H; Yang H; Xia Y
    Curr Pharm Biotechnol; 2018; 19(1):79-86. PubMed ID: 29667551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
    Balsa A; Sanmarti R; Rosas J; Martin V; Cabez A; Gómez S; Montoro M
    Rheumatology (Oxford); 2018 Apr; 57(4):688-693. PubMed ID: 29365183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating miR-99b-5p as a novel predictor of erosion progression on high-resolution peripheral quantitative computed tomography in early rheumatoid arthritis: A prospective cohort study.
    Yue J; Lau TCK; Griffith JF; Xu J; Xiao F; Shi L; Wang D; Wong PCH; Li EK; Tam LP; Li M; Li TK; Mak WY; Hung V; Qin L; Tam LS
    Int J Rheum Dis; 2019 Sep; 22(9):1724-1733. PubMed ID: 31273939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ex vivo inhibited cytokine profiling may explain inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis.
    Tweehuysen L; Schraa K; Netea MG; van den Hoogen FHJ; Joosten LAB; den Broeder AA
    Clin Exp Rheumatol; 2018; 36(1):140-143. PubMed ID: 29148425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study.
    Sfriso P; Caso F; Filardo GS; Botsios C; Costa L; Scarpa R; Todesco S; Spinella P; Oliviero F; Punzi L
    Clin Rheumatol; 2016 Jun; 35(6):1615-8. PubMed ID: 27048267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteomics to predict the response to tumour necrosis factor-α inhibitors in rheumatoid arthritis using a supervised cluster-analysis based protein score.
    Cuppen B; Fritsch-Stork R; Eekhout I; de Jager W; Marijnissen AC; Bijlsma J; Custers M; van Laar JM; Lafeber F; Welsing P;
    Scand J Rheumatol; 2018 Jan; 47(1):12-21. PubMed ID: 28650254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of circulating miR-146a in patients with rheumatoid arthritis treated by Tripterygium wilfordii Hook F.
    Chen ZZ; Zhang XD; Chen Y; Wu YB
    Medicine (Baltimore); 2017 May; 96(20):e6775. PubMed ID: 28514293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.